慢阻肺识别与长期管理：从肺功能确诊到减少急性加重

先看懂四件事：谁会得慢阻肺、怎么确诊、怎么减少加重、怎么长期管理COPD Recognition & Long-Term Management

慢阻肺是一条可以干预的长期通道：危险因素暴露（吸烟、生物质燃料烟雾、职业粉尘）→ 气道慢性炎症与肺实质破坏 → 气流受限不完全可逆 → 症状与急性加重 → 通过戒烟、规范吸入治疗、疫苗、肺康复与必要的氧疗减少加重、维持生活质量。识别得越早，能保住的活动能力越多。

发病机理：气道与肺实质的慢性损伤Pathogenesis

慢阻肺不是单纯「气管发炎」：小气道狭窄与黏液增多让呼吸费力，肺实质破坏（肺气肿）让肺失去弹性回缩力，两者叠加造成不可完全逆转的气流受限。理解这条链条，才能理解为什么戒烟、吸入治疗与肺康复要长期坚持。

哪些因素增加慢阻肺与急性加重风险

两个容易被忽略的问题

怎么检查：从肺功能到共病评估Assessment

怎么治疗：吸入治疗、减少加重与非药物管理Treatment

治疗与预防一览

日常管理：避免加重与长期随访Daily Management

十个常见误区Ten Common Misconceptions

参考文献与证据来源References & Evidence

本页共 24 条文献，来自国际共识与指南、随机对照试验、荟萃分析与机制研究，链接指向 PubMed。每条结论后的编号对应下方文献；证据不足或结论不一致之处已在正文标注。

1. 全国横断面调查（中国慢阻肺患病率与危险因素：CPH 研究，50,991 人）Wang C, Xu J, Yang L, Xu Y, Zhang X, Bai C, Kang J, Ran P, Shen H, Wen F, Huang K, Yao W, Sun T, Shan G, Yang T, Lin Y, Wu S, Zhu J, Wang R, Shi Z, Zhao J, Ye X, Song Y, Wang Q, Zhou Y, Ding L, Yang T, Chen Y, Guo Y, Xiao F, Lu Y, Peng X, Zhang B, Xiao D, Chen CS, Wang Z, Zhang H, Bu X, Zhang X, An L, Zhang S, Cao Z, Zhan Q, Yang Y, Cao B, Dai H, Liang L, He J, China Pulmonary Health Study Group. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study. Lancet. 2018;391(10131):1706-1717. pubmed.ncbi.nlm.nih.gov/29650248
2. 指南执行摘要（GOLD 2023：慢阻肺诊断、分级与分组标准）Agustí A, Celli BR, Criner GJ, Halpin D, Anzueto A, Barnes P, Bourbeau J, Han MK, Martinez FJ, Montes de Oca M, Mortimer K, Papi A, Pavord I, Roche N, Salvi S, Sin DD, Singh D, Stockley R, López Varela MV, Wedzicha JA, Vogelmeier CF. Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary. Am J Respir Crit Care Med. 2023;207(7):819-837. pubmed.ncbi.nlm.nih.gov/36856433
3. 指南文件（肺功能检查的判读策略）Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, Coates A, van der Grinten CP, Gustafsson P, Hankinson J, Jensen R, Johnson DC, MacIntyre N, McKay R, Miller MR, Navajas D, Pedersen OF, Wanger J. Interpretative strategies for lung function tests. Eur Respir J. 2005;26(5):948-968. pubmed.ncbi.nlm.nih.gov/16264058
4. 队列随访研究（通向慢阻肺的肺功能轨迹）Lange P, Celli B, Agustí A, Boje Jensen G, Divo M, Faner R, Guerra S, Marott JL, Martinez FD, Martinez-Camblor P, Meek P, Owen CA, Petersen H, Pinto-Plata V, Schnohr P, Sood A, Soriano JB, Tesfaigzi Y, Vestbo J. Lung-Function Trajectories Leading to Chronic Obstructive Pulmonary Disease. N Engl J Med. 2015;373(2):111-122. pubmed.ncbi.nlm.nih.gov/26154786
5. 系统评价与荟萃分析（生物质燃料使用与女性慢阻肺风险）Sana A, Somda SMA, Meda N, Bouland C. Chronic obstructive pulmonary disease associated with biomass fuel use in women: a systematic review and meta-analysis. BMJ Open Respir Res. 2018;5(1):e000246. pubmed.ncbi.nlm.nih.gov/29387422
6. Cochrane 系统评价（尼古丁替代治疗与戒烟）Hartmann-Boyce J, Chepkin SC, Ye W, Bullen C, Lancaster T. Nicotine replacement therapy versus control for smoking cessation. Cochrane Database Syst Rev. 2018;5():CD000146. pubmed.ncbi.nlm.nih.gov/29852054
7. 随机对照试验（沙美特罗／氟替卡松与慢阻肺生存：TORCH）Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J, TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356(8):775-789. pubmed.ncbi.nlm.nih.gov/17314337
8. 随机对照试验（单吸入器三联与双联治疗比较：IMPACT，10,355 例）Lipson DA, Barnhart F, Brealey N, Brooks J, Criner GJ, Day NC, Dransfield MT, Halpin DMG, Han MK, Jones CE, Kilbride S, Lange P, Lomas DA, Martinez FJ, Singh D, Tabberer M, Wise RA, Pascoe SJ, IMPACT Investigators. Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD. N Engl J Med. 2018;378(18):1671-1680. pubmed.ncbi.nlm.nih.gov/29668352
9. 随机对照试验（两种激素剂量的三联吸入治疗：ETHOS，8,509 例）Rabe KF, Martinez FJ, Ferguson GT, Wang C, Singh D, Wedzicha JA, Trivedi R, St Rose E, Ballal S, McLaren J, Darken P, Aurivillius M, Reisner C, Dorinsky P, ETHOS Investigators. Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD. N Engl J Med. 2020;383(1):35-48. pubmed.ncbi.nlm.nih.gov/32579807
10. 随机试验死亡率分析（ETHOS 全因死亡分析）Martinez FJ, Rabe KF, Ferguson GT, Wedzicha JA, Singh D, Wang C, Rossman K, St Rose E, Trivedi R, Ballal S, Darken P, Aurivillius M, Reisner C, Dorinsky P. Reduced All-Cause Mortality in the ETHOS Trial of Budesonide/Glycopyrrolate/Formoterol for Chronic Obstructive Pulmonary Disease. A Randomized, Double-Blind, Multicenter, Parallel-Group Study. Am J Respir Crit Care Med. 2021;203(5):553-564. pubmed.ncbi.nlm.nih.gov/33252985
11. 随机对照试验（超细颗粒三联与双联支气管扩张剂比较：TRIBUTE）Papi A, Vestbo J, Fabbri L, Corradi M, Prunier H, Cohuet G, Guasconi A, Montagna I, Vezzoli S, Petruzzelli S, Scuri M, Roche N, Singh D. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet. 2018;391(10125):1076-1084. pubmed.ncbi.nlm.nih.gov/29429593
12. 荟萃分析（吸入激素与慢阻肺患者肺炎风险：59 项 RCT、103,477 例）Chen H, Sun J, Huang Q, Liu Y, Yuan M, Ma C, Yan H. Inhaled Corticosteroids and the Pneumonia Risk in Patients With Chronic Obstructive Pulmonary Disease: A Meta-analysis of Randomized Controlled Trials. Front Pharmacol. 2021;12():691621. pubmed.ncbi.nlm.nih.gov/34267661
13. Cochrane 系统评价（抗生素治疗慢阻肺急性加重）Vollenweider DJ, Frei A, Steurer-Stey CA, Garcia-Aymerich J, Puhan MA. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2018;10():CD010257. pubmed.ncbi.nlm.nih.gov/30371937
14. Cochrane 系统评价（全身激素治疗慢阻肺急性加重）Walters JA, Tan DJ, White CJ, Gibson PG, Wood-Baker R, Walters EH. Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2014;(9):CD001288. pubmed.ncbi.nlm.nih.gov/25178099
15. Cochrane 系统评价（无创正压通气治疗慢阻肺急性加重所致呼吸衰竭）Lightowler JV, Wedzicha JA, Elliott MW, Ram FS. Non-invasive positive pressure ventilation to treat respiratory failure resulting from exacerbations of chronic obstructive pulmonary disease: Cochrane systematic review and meta-analysis. BMJ. 2003;326(7382):185. pubmed.ncbi.nlm.nih.gov/12543832
16. 随机对照非劣效试验（高流量鼻导管氧疗与无创通气在急性加重伴高碳酸血症中的比较）Tan D, Wang B, Cao P, Wang Y, Sun J, Geng P, Walline JH, Wang Y, Wang C. High flow nasal cannula oxygen therapy versus non-invasive ventilation for acute exacerbations of chronic obstructive pulmonary disease with acute-moderate hypercapnic respiratory failure: a randomized controlled non-inferiority trial. Crit Care. 2024;28(1):250. pubmed.ncbi.nlm.nih.gov/39026242
17. Cochrane 系统评价（慢阻肺肺康复，65 项 RCT、3,822 例）McCarthy B, Casey D, Devane D, Murphy K, Murphy E, Lacasse Y. Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2015;(2):CD003793. pubmed.ncbi.nlm.nih.gov/25705944
18. Cochrane 系统评价（急性加重后的肺康复）Puhan MA, Gimeno-Santos E, Cates CJ, Troosters T. Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2016;12():CD005305. pubmed.ncbi.nlm.nih.gov/27930803
19. 随机对照试验（长期家庭氧疗治疗慢性低氧性肺心病：MRC 工作组） Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working Party. Lancet. 1981;1(8222):681-686. pubmed.ncbi.nlm.nih.gov/6110912
20. 随机对照试验（中度低氧慢阻肺的长期氧疗：LOTT，738 例）Long-Term Oxygen Treatment Trial Research Group, Albert RK, Au DH, Blackford AL, Casaburi R, Cooper JA, Criner GJ, Diaz P, Fuhlbrigge AL, Gay SE, Kanner RE, MacIntyre N, Martinez FJ, Panos RJ, Piantadosi S, Sciurba F, Shade D, Stibolt T, Stoller JK, Wise R, Yusen RD, Tonascia J, Sternberg AL, Bailey W. A Randomized Trial of Long-Term Oxygen for COPD with Moderate Desaturation. N Engl J Med. 2016;375(17):1617-1627. pubmed.ncbi.nlm.nih.gov/27783918
21. 随机对照试验（家庭无创通气联合氧疗与单纯氧疗：再住院或死亡）Murphy PB, Rehal S, Arbane G, Bourke S, Calverley PMA, Crook AM, Dowson L, Duffy N, Gibson GJ, Hughes PD, Hurst JR, Lewis KE, Lewis KE, Mukherjee R, Nickol A, Oscroft N, Patout M, Pepperell J, Smith I, Stradling JR, Wedzicha JA, Polkey MI, Elliott MW, Hart N. Effect of Home Noninvasive Ventilation With Oxygen Therapy vs Oxygen Therapy Alone on Hospital Readmission or Death After an Acute COPD Exacerbation: A Randomized Clinical Trial. JAMA. 2017;317(21):2177-2186. pubmed.ncbi.nlm.nih.gov/28528348
22. Cochrane 系统评价（慢阻肺患者的流感疫苗）Kopsaftis Z, Wood-Baker R, Poole P. Influenza vaccine for chronic obstructive pulmonary disease (COPD). Cochrane Database Syst Rev. 2018;6():CD002733. pubmed.ncbi.nlm.nih.gov/29943802
23. 随机对照试验（多糖结合疫苗预防成人肺炎球菌肺炎）Bonten MJ, Huijts SM, Bolkenbaas M, Webber C, Patterson S, Gault S, van Werkhoven CH, van Deursen AM, Sanders EA, Verheij TJ, Patton M, McDonough A, Moradoghli-Haftvani A, Smith H, Mellelieu T, Pride MW, Crowther G, Schmoele-Thoma B, Scott DA, Jansen KU, Lobatto R, Oosterman B, Visser N, Caspers E, Smorenburg A, Emini EA, Gruber WC, Grobbee DE. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med. 2015;372(12):1114-1125. pubmed.ncbi.nlm.nih.gov/25785969
24. 系统评价与荟萃分析（慢阻肺与心血管疾病、慢性肾脏病及死亡风险）Joseph T, Gao C, Nadarajah R, Al-Lehebi R, Alves L, Berg DD, Couper A, Datta I, Eleyan L, Haris M, Hawkins N, Hurst JR, Jenkins CR, Kaplan A, Kocks JWH, Kostikas K, Lam CS, Laperre T, Martinez F, Mircescu A, Montero Arias MF, Nadeem U, Nguyen L, Wignall K, Pullen R, Raveendra K, Rhee CK, Sattar N, Stolz D, Sun Y, Tse G, Winders T, Price DB, Bhutani M, Wu J, Gale CP. Chronic obstructive pulmonary disease and risk of incident cardiovascular disease, chronic kidney disease, and death: a systematic review and meta-analysis. EClinicalMedicine. 2026;98():104131. pubmed.ncbi.nlm.nih.gov/42602993